When 10 mg Biotin Tablets Are Manufactured by Direct Compression

Direct compression of high-strength biotin tablets at 10 mg per unit is executed on a rotary press with a pre-compression station, typically with a 500 mg core weight. At this dose and core mass, biotin constitutes 2.0% w/w; a 300 µg strength in a 200 mg core corresponds to 0.15% w/w, while a 5 mg strength in a 350 mg core gives 1.43% w/w. CEP-grade biotin is controlled against Ph. Eur. monograph 1073 and the USP–NF Biotin monograph, and finished-tablet uniformity of dosage units is governed by Ph. Eur. 2.9.40 and USP <905>; dissolution, where required, follows USP <711> or Ph. Eur. 2.9.3, and disintegration is assessed per USP <701> and Ph. Eur. 2.9.1.

Manufacturing begins with de-agglomeration of biotin through a conical screen fitted with a 500 µm screen; if the CEP certificate reports a D90 above 100 µm, a micronized or air-jet-milled source is selected to avoid content uniformity drift. A geometric pre-blend is prepared with lactose monohydrate or dibasic calcium phosphate dihydrate at 1:5 then 1:10 ratios in a low-shear tumble blender at 12–18 rpm for 15–20 min. The main filler is microcrystalline cellulose with dibasic calcium phosphate dihydrate at a 70:30 ratio; croscarmellose sodium at 2.0–3.0% w/w serves as disintegrant. Magnesium stearate is added at 0.5–1.0% w/w and total lubrication time is limited to 3–5 min because over-lubrication reduces tablet tensile strength. Compression is run at 8–15 kN main compression force with 2–4 kN pre-compression, targeting hardness of 80–110 N for the 10 mg tablet. The finished dosage form is a film-coated or uncoated oral tablet for nutritional or dermatological indications. Direct compression becomes less suitable below approximately 0.1% w/w biotin because static adhesion and segregation require extensive pre-blending; published data for this specific configuration is limited below this threshold.

In low-dose hard capsule manufacture, biotin at 1.0 mg per size 3 capsule is incorporated as a pre-blend that keeps the API fraction at 0.56% w/w when the total fill weight is 180 mg; for 2.5 mg in a size 1 capsule of 300 mg, the fraction is 0.83% w/w. Compliance follows Ph. Eur. 2.9.40 for uniformity of dosage units and Ph. Eur. 2.9.1 for hard capsule disintegration in water at 37±2 °C, with complete disintegration expected within 30 min for gelatin shells; HPMC capsules are tested under the same apparatus but may show longer shell rupture lag. The production route uses a low-dose premix of biotin with lactose monohydrate at 1:5 and 1:10 stages, followed by blending with pregelatinized starch or microcrystalline cellulose as filler. Colloidal silicon dioxide is added at 0.1–0.5% w/w as glidant. Capsule filling on a tamping-pin machine, such as a Bosch GKF-series or MG2 Planeta-class encapsulator, requires pin penetration depth and tamping force to be adjusted to prevent powder compaction. The fill weight relative standard deviation should be held below 3.0% RSD for low-dose strengths; dosator equipment can create weight variability if powder feed is too aerated. Environmental controls maintain 20–25 °C and 35–45% RH because gelatin shells become brittle below 40% RH and soften above 60% RH. Static adhesion to contact parts is mitigated by ionization bars and grounding of transfer lines. The finished product type is hard gelatin or hydroxypropyl methylcellulose capsule. Operational boundaries include pre-drying at ambient RH above 60% because moisture uptake in the fine lactose pre-blend alters fill density and content uniformity.

For sachet granules with a 5 mg biotin payload in a 5 g dose, the API fraction is 0.1% w/w, and top-spray fluid-bed granulation is used instead of high-shear wet granulation because the low drug load requires continuous suspension of the API in the binder phase. Compliance for the granule-filled stick pack is assessed under Ph. Eur. 2.9.40 for uniformity of dosage units and Ph. Eur. 2.9.1 if the granules are dispersed before administration; residual moisture after drying is controlled to ≤2.0% w/w by loss on drying. Biotin CEP grade is dispersed in an aqueous povidone K30 binder solution at 2.0–5.0% w/w of total dry granule mass. The fluid-bed inlet air temperature is set at 50–60 °C, product temperature at 28–32 °C, and spray rate at 20–30 g/min for a 2 kg batch scale; after granulation, the mass is dried to target moisture and milled through a 1000 µm screen. Fines below 150 µm are kept below 20% w/w to reduce segregation during stick-pack filling. The granule matrix contains mannitol as a soluble filler and crospovidone at 2.0% w/w to aid dispersion. Finished products are single-dose stick packs or sachets containing oral granules to be dissolved or suspended in water. API migration during drying is a known failure mode; if the binder is sprayed too wet or the drying rate is uneven, dissolved biotin can reconcentrate at the granule surface and cause assay variation. Maintaining a moderate liquid addition and avoiding inlet temperatures above 60 °C limits this migration; published data for biotin-specific migration kinetics in this formulation system is limited.

What Limits Batch Homogeneity in Biotin Oral Solutions at 100 µg/mL?

Batch homogeneity in a 100 µg/mL oral solution is controlled first by the solubility boundary of biotin in water; published values are near 0.22 mg/mL at 25 °C, so the target concentration of 0.1 mg/mL is below saturation but still requires defined dissolution time. The addition ratio is 0.01% w/v for a 1000 mL solution containing 100 mg biotin CEP grade. For non-sterile oral liquids, microbial quality is assessed by Ph. Eur. 5.1.4; if the container is multidose, antimicrobial preservation effectiveness testing follows Ph. Eur. 5.1.3. The API itself is controlled against Ph. Eur. monograph 1073, and elemental impurities are aligned with ICH Q3D. The manufacturing vessel is a jacketed stainless-steel tank with counter-rotating mixer; purified water is heated to 40–50 °C, and biotin is added gradually under continuous agitation at 200–400 rpm. The pH is adjusted with dilute hydrochloric acid or sodium hydroxide to 6.5–7.5; avoiding pH above 8.0 reduces alkaline degradation risk. Non-crystallizing sorbitol liquid is used as a sweetener at 15–25% w/v, and potassium sorbate at 0.1–0.2% w/v may be added if preservation is required. The solution is passed through a 0.45 µm polyethersulfone membrane before filling into amber glass dropper bottles. The terminal dosage form is an oral solution or syrup, often with a dropper for pediatric or adult supplementation. Oxygen and light exposure are controlled by amber glass and nitrogen sparging of the receiving vessel; solution stability is lowest when trace metal contaminants are present, so stainless-steel contact surfaces are passivated and the water system is monitored for conductivity and total organic carbon.

Dissolution of injectable-grade biotin in Water for Injections under a nitrogen overlay yields a single-dose ampoule solution at 1.0 mg/mL, equivalent to 0.1% w/v biotin CEP grade. The injectable route adds three additional compliance layers: sterility testing per Ph. Eur. 2.6.1, bacterial endotoxin testing per Ph. Eur. 2.6.14, and sub-visible particulate matter testing per Ph. Eur. 2.9.19 and 2.9.20. The water for injection is controlled under Ph. Eur. monograph 0169; the rubber stopper and ampoule glass must meet Ph. Eur. 3.2.1 or 3.2.9 compatibility requirements. Dissolution is performed in a jacketed vessel at 30–40 °C with sodium chloride added to isotonicity at 0.9% w/v. The pH is adjusted to 6.0–7.0 with 0.1 N hydrochloric acid or sodium hydroxide under monitored conductivity. The solution is filtered through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane and then filled into amber ampoules under nitrogen atmosphere. Terminal sterilization is performed at 121 °C for 15 min, giving an F0 above 8.0; if terminal sterilization data are not available for a given formulation, aseptic filling is used with filter integrity tests before and after filling. The finished product is an IV or IM injection solution supplied in glass ampoules or vials. Biotin is not compatible with strong oxidizing agents; filling lines using silicone tubing should be validated for extractables because trace leachables can accelerate assay loss. Published data for biotin-specific adsorption to tubing and stoppers is limited, so hold-time studies at intermediate bulk stage are required for each line.

Biotin Dispersible Tablets and the Citric Acid–Sodium Bicarbonate Effervescent Route

Effervescent biotin tablets are compacted under low humidity because the acid and carbonate components are physically separated until the tablet is dropped into water. At a 5 mg dose in a 4.0 g effervescent tablet, the biotin fraction is 0.125% w/w; at 2.5 mg in a 3.5 g tablet, it is 0.071% w/w. Disintegration is tested by Ph. Eur. 2.9.1 for effervescent tablets, with the acceptance expectation of complete disintegration in 200 mL water at 20±5 °C within 5 min; content uniformity is per Ph. Eur. 2.9.40. The effervescent base contains anhydrous citric acid at 20–25% w/w, sodium bicarbonate at 30–40% w/w, sodium carbonate at 10–15% w/w, mannitol as filler, and polyethylene glycol 6000 at 2.5% w/w as internal lubricant/binder. Because moist granulation would initiate premature acid–base reaction, dry granulation by slugging or roller compaction is used. Biotin is incorporated via a pre-blend with mannitol at 1:10 before roller compaction; the granulate is milled to 800–1000 µm and lubricated with sodium stearyl fumarate at 1.0–1.5% w/w. Compression is performed in an environment with relative humidity below 20% RH at 20–22 °C, using stainless steel punches and a rotary press with dust extraction to prevent carbon dioxide release and tablet capping. The terminal dosage form is an effervescent tablet that generates a clear or slightly opalescent oral solution when dispersed in water. Pre-drying of the granulate is required when residual moisture exceeds 2.0% w/w. Packaging must use aluminum foil strips with low water vapour transmission rates, typically below 0.1 g/m²/day at 38 °C/90% RH, to prevent moisture ingress and premature effervescence.